Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Aktuelle Daten zum Malignen Melanom

Prof. Dr. Jochen Utikal, ab S. 11

  1. Adil Daud, Christian U. Blank, Caroline Robert, Igor Puzanov, Erika Richtig, Kim Allyson Margolin, Steven O'Day, Marta Nyakas, Jose Lutzky, Ahmad A. Tarhini, Elaine McWhirter, Christian Caglevic, Peter Mohr, Michael Millward, Marcus O. Butler, Honghong Zhou, Kenneth Emancipator, Scot Ebbinghaus, Nageatte Ibrahim, Georgina V. Long. KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. J Clin Oncol 34, 2016 (suppl; abstr 9513)
  2. Reinhard Dummer, Dirk Schadendorf, Paolo Antonio Ascierto, Ana Maria Arance Fernández, Caroline Dutriaux, Michele Maio, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandalà, Luc Thomas, Ernesto Wasserman, James Ford, Marine Weill, L. Andres Sirulnik, Valentine Jehl, Viviana Bozon, Georgina V. Long, Keith Flaherty. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J Clin Oncol 34, 2016 (suppl; abstr 9500)
  3. Keith Flaherty, Michael A. Davies, Jean Jacques Grob, Georgina V. Long, Paul D. Nathan, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Dennie T Frederick, Marc R Hammond, Judit Jane-Valbuena, Xinmeng Jasmine Mu, Matthew Squires, Savina A. Jaeger, Stephen R. Lane, Bijoyesh Mookerjee, Levi A. Garraway. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. J Clin Oncol 34, 2016 (suppl; abstr 9502) 
  4. Jessica Cecile Hassel, Andrea Forschner, Leonie Blum, Lucie Heinzerling, Lisa Zimmer, Jochen Utikal, Katharina C. Kähler, Max Schlaak, Carmen Loquai, Ralf Gutzmer, Felix Kiecker, Carola Berking, Armin Bender, Lars Schneider, Alexander Enk, Claus Garbe, Michael Weichenthal, Dirk Schadendorf, Axel Hauschild, Peter Mohr; Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP). J Clin Oncol 34, 2016 (suppl; abstr 9558)
  5. James M. G. Larkin, Grant A. McArthur, Antoni Ribas, Paolo Antonio Ascierto, Jorge D Gallo, Isabelle Anne Rooney, Ilsung Chang, Brigitte Drén; Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM). J Clin Oncol 34, 2016 (suppl; abstr 9528)
  6. Georgina V. Long, Omid Hamid, F. Stephen Hodi, Donald P. Lawrence, Victoria Atkinson, Alexander Starodub, Matteo S. Carlino, Rosalie Anne Fisher, Wilson H Miller, Michele Maio, Marcus Butler, Paola Queirolo, Pier Francesco Ferrucci, Teresa M. Petrella, Jacob Schachter, Yingjie Huang, Scott J. Diede, Scot Ebbinghaus, Antoni Ribas. Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022). J Clin Oncol 34, 2016 (suppl; abstr TPS9596) (a)
  7. Georgina V. Long, Reinhard Dummer, Antoni Ribas, Igor Puzanov, Ari VanderWalde, Robert Hans Ingemar Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan S. Cebon, Eugenio Fernandez, John M. Kirkwood, Thomas Gajewski, Christine K. Gause, Lisa Chen, Kevin Gorski, Abraham Anderson, David Ross Kaufman, Jeffrey Chou, F. Stephen Hodi. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.  Clin Oncol 34, 2016 (suppl; abstr 9568) (b)
  8. Antoni Ribas, F. Stephen Hodi, Donald P. Lawrence, Victoria Atkinson, Alexander Starodub, Matteo S. Carlino, Rosalie Anne Fisher, Georgina V. Long, Wilson H Miller, Yingjie Huang, Scott J. Diede, Scot Ebbinghaus, Omid Hamid. Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. J Clin Oncol 34, 2016 (suppl; abstr 3014)
  9. Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard Wayne Joseph, Roxana Stefania Dronca, Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Xiaoyun Li, Scott J. Diede, Scot Ebbinghaus, F. Stephen Hodi; Gustave Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 34, 2016 (suppl; abstr 9503)
  10. Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James M. G. Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert; Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. J Clin Oncol 34, 2016 (suppl; abstr 9504)
  11. Simone Stadler, Kasia Weina, Christoffer Gebhardt, Jochen Utikal. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci 60:83-8, 2015.
  12. Jeffrey S. Weber, Geoffrey Thomas Gibney, Ryan J. Sullivan, Jeffrey Alan Sosman, Craig L. Slingluff, Donald P. Lawrence, Theodore F. Logan, Lynn Mara Schuchter, Suresh Nair, Elizabeth Iannotti Buchbinder, Elmer Berghorn, Joel Jiang, Christine E. Horak, F. Stephen Hodi. Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). J Clin Oncol 34, 2016 (suppl; abstr 9517)
  13. Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean Jacques Grob, C. Lance Cowey, Christopher Lao, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, John B. A. G. Haanen, Michele Maio, Grant A. McArthur, Dana Walker, Joel Jiang, Christine E. Horak, James M. G. Larkin, F. Stephen Hodi. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol 34, 2016 (suppl; abstr 9505)

Klinische Entwicklungen zum Lungenkarzinom

PD Dr. Martin Steins, ab S. 14

  1. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12: 175-180
  2. Denis F, Lethrosne C, Pourel N et al.: Overall survival in patients with lung cancer using a web-application-guided follow-up compared to standard modalities: Results of phase III randomized trial. J Clin Oncol 2016, 34 (suppl.): abstr. LBA9006
  3. Des Guetz G, Landre T, Nicolas P et al.: Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis. J Clin Oncol 2016, 34 (suppl.): abstr. e2055
  4. Borghaei H, Brahmer JR, Horn L et al.: Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. J Clin Oncol 2016, 34 (suppl.): abstr. 9025
  5. Fachinformation OPDIVO® 10 mg/ml. Stand: Mai 2016. Bristol-Myers Squibb, Uxbridge, UK. Zulassungsnummer: EU /1/15/1014/001-002
  6. Garon EB, Herbst RS, Kim DW et al.: Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. J Clin Oncol 2016, 34 (suppl.): abstr. 9024
  7. Goldman GJW, Soria JC, Wakelee HA et al.: Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2016, 34 (suppl.): abstr. 9045
  8. Tan DSW, Yang JCH, Leighl NB et al.: Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J Clin Oncol 2016, 34 (suppl.): abstr. 9044
  9. Park K, Lee JS, Lee KH et al.: BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D. J Clin Oncol 2016, 34 (suppl.): abstr. 9055
  10. Wakelee HA, Gadgeel SM, Goldman JW et al.: Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J Clin Oncol 2016, 34 (suppl.): abstr. 9001 
  11. Shaw AT, Kim DW, Nakagawa K et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368: 2385-2394
  12. Shaw AT, Kim DW, Mehra R et al.: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370: 1189-1197
  13. Yang JCH, Ou SHI, De Petris L et al.: Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761). J Clin Oncol 2016, 34 (suppl.): abstr. e20507
  14. Nokihara H, Hida T, Kondo M et al.: Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol 2016, 34 (suppl.): abstr. 9008
  15. Kim DW, Tiseo M, Ahn MJ et al.: Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). J Clin Oncol 2016, 34 (suppl.): abstr. 9007
  16. Solomon BJ, Bauer TM, Felip E et al.: Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). J Clin Oncol 2016, 34 (suppl.): abstr. 9009
  17. Planchard D, Besse B, Groen HJ et al.: Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 2016, pii: S1470-2045(16)30146-2. doi: 10.1016/S1470-2045(16)30146-2
  18. Planchard D, Besse B, Groen HJ et al.: An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol 2016, 34 (suppl.): abstr. 107
  19. Gautschi O, Wolf J, Milia J et al.: Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. J Clin Oncol 2016, 34 (suppl.): abstr. 9014 
  20. Seto T, Yoh K, Satouchi M et al.: A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. J Clin Oncol 2016, 34 (suppl.): abstr. 9012
  21. Lee SH, Lee JK, Ahn MJ et al.: A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. J Clin Oncol 2016, 34 (suppl.): abstr. 9013
  22. Li AN, Yang JJ, Zhang X: Impact of different MET alterations on the efficacy of crizotinib in non-small-cell lung cancer. J Clin Oncol 2016, 34 (suppl.): abstr. e20622
  23. Drilon AE, Camidge DR, Ou SHI et al.: Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol 2016, 34 (suppl.): abstr. 108
  24. Barlesi F, Raimbourg J, Do P et al.: A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer). J Clin Oncol 2016, 34 (suppl.): abstr. 9077
  25. Ardizonni A, Boni L, Tiseo M et al.: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99: 847-857
  26. Cortot AB, Audigier-Valette C, Molinier O et al.: Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE. J Clin Oncol 2016, 34 (suppl.): abstr. 9005
  27. Reck M, Kaiser R, Mellemgaard A et al.: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15:143-155
  28. Garon EB, Ciuleanu TE, Arrieta O et al.: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014, 384: 665-673   
  29. Reck M, Paz-Ares LG, Bidoli P et al.: Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). J Clin Oncol 2016, 34 (suppl.): abstr. 9079

Aktuelle Ergebnisse zum Mammakarzinom

PD Dr. med. Andreas Hartkopf, ab S. 24

  1. Cortazar, P, Zhang, L, Untch, M, Mehta, K, Costantino, JP, Wolmark, N, Bonnefoi, H, Cameron, D, Gianni, L, Valagussa, P, Swain, SM, Prowell, T, Loibl, S, Wickerham, DL, Bogaerts, J, Baselga, J, Perou, C, Blumenthal, G, Blohmer, J, Mamounas, EP, Bergh, J, Semiglazov, V, Justice, R, Eidtmann, H, Paik, S, Piccart, M, Sridhara, R, Fasching, PA, Slaets, L, Tang, S, Gerber, B, Geyer, CE, Jr., Pazdur, R, Ditsch, N, Rastogi, P, Eiermann, W and von Minckwitz, G, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 2014. 384(9938): p. 164-72.
  2. Gianni, L, Pienkowski, T, Im, YH, Roman, L, Tseng, LM, Liu, MC, Lluch, A, Staroslawska, E, de la Haba-Rodriguez, J, Im, SA, Pedrini, JL, Poirier, B, Morandi, P, Semiglazov, V, Srimuninnimit, V, Bianchi, G, Szado, T, Ratnayake, J, Ross, G and Valagussa, P, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012. 13(1): p. 25-32.
  3. Schneeweiss, A, Chia, S, Hickish, T, Harvey, V, Eniu, A, Hegg, R, Tausch, C, Seo, JH, Tsai, YF, Ratnayake, J, McNally, V, Ross, G and Cortes, J, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 2013. 24(9): p. 2278-84.
  4. Davies, C, Pan, H, Godwin, J, Gray, R, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, VH, Badran, A, Bonfill, X, Bradbury, J, Clarke, M, Collins, R, Davis, SR, Delmestri, A, Forbes, JF, Haddad, P, Hou, MF, Inbar, M, Khaled, H, Kielanowska, J, Kwan, WH, Mathew, BS, Mittra, I, Muller, B, Nicolucci, A, Peralta, O, Pernas, F, Petruzelka, L, Pienkowski, T, Radhika, R, Rajan, B, Rubach, MT, Tort, S, Urrutia, G, Valentini, M, Wang, Y, Peto, R and Adjuvant Tamoxifen: Longer Against Shorter Collaborative, G, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 2013. 381(9869): p. 805-16.
  5. Giuliano, AE, McCall, LM, Beitsch, PD, Whitworth, PW, Morrow, M, Blumencranz, PW, Leitch, AM, S. Saha, K. Hunt and Ballman, KV, COSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol, 2010. 28(18s): abstr CRA506.
  6. Finn, RS, Crown, JP, Lang, I, Boer, K, Bondarenko, IM, Kulyk, SO, Ettl, J, Patel, R, Pinter, T, Schmidt, M, Shparyk, Y, Thummala, AR, Voytko, NL, Fowst, C, Huang, X, Kim, ST, Randolph, S and Slamon, DJ, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol, 2015. 16(1): p. 25-35.
  7. Cristofanilli, M, Turner, NC, Bondarenko, I, Ro, J, Im, SA, Masuda, N, Colleoni, M, DeMichele, A, Loi, S, Verma, S, Iwata, H, Harbeck, N, Zhang, K, Theall, KP, Jiang, Y, Bartlett, CH, Koehler, M and Slamon, D, Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016. 17(4): p. 425-39.
  8. Petrelli, F and Barni, S, Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol, 2012. 29(5): p. 3282-90.
  9. Badwe, R, Hawaldar, R, Nair, N, Kaushik, R, Parmar, V, Siddique, S, Budrukkar, A, Mittra, I and Gupta, S, Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol, 2015. 16(13): p. 1380-8.
  10. Soran A., Ozmen V., Ozbas S., Karanlik H., Muslumanoglu M., Igci A., Canturk Z., Utkan Z., Ozaslan C., Evrensel T., Uras C., Aksaz E., Soyder A., Ugurlu U., Col C., Cabioglu N., Bozkurt B., Dagoglu T., Uzunkoy A., Dulger M., Koksal N., Cengiz O., Gulluoglu B., Unal B., Atalay C., Yildirim E., Erdem E., Salimoglu S., Sezer A., Koyuncu A., Gurleyik G., Alagol H., Ulufi N., Berberoglu U., Kennard E., Kelsey S. and B., L, Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). San Antonio Breast Cancer Symposium, 2013: abstr. S2-03.

Target orientierte Therapie des fortgeschrittenen Prostatakarzinoms

Prof. Dr. Thomas Otto, ab S. 28

  1. Antonarakis ES Randomized phase II study evaluating the optimal sequencing of sipuleucel T and androgen deprivation therapy in biochemically recurrent prostate cancer: Preliminary clinical data. J Clin Oncol suppl. 5041, 2014.
  2. Antonarakis ES, ASCO GU: 138, 2015.
  3. Basch EM et al. Final analysis of COMET-2. ASCO GU 141,2015.
  4. Beer TM et al. Enzalutamide in men with chemotherapy naïve mCRPC. J Clin Oncol 33 e 5036, 2015.
  5. Carreira JMS DNA repair defects and Olaparib im metastatic prostate cancer. NEJM 373(18):16971708,2015.
  6. Castellano D et al. Early access protocol with abiraterone acetate for european patients with metastatic castration resistant prostate cancer progressing after chemotherapy. Eur Urol Suppl 14/2;557 e, 2015.
  7. De Bono JS Phase II randomized study of Figitumumab plus docetaxel and docetaxel alone with crossover of mCRPC. Clin Cancer Res PMID:24536060,2014.
  8. De Santis M et al. First prospective open –label, phase II study of sipuleucel-T in European men with mCRPC. J Clin Oncol 33 e 16015, 2015.
  9. De Wit RD Phase 3 randomized placebo controlled trial of orteronel plus prednisone in patients with chemonaive mCRPC. J Clin Oncol suppl. 5033, 2014.
  10. Drake CG Results of subset analyses on overall survival from CA 184-043: Ipilimumab versus placebo in post docetaxel mCRPC. J Clin Oncol (suppl.), 2014.
  11. Dreicer R Results from a phase 3, randomized ,double blind, multicenter, placebo controlled trial of orteronel plus prednisone in patients witm mCRPC that has progressed during or following docetaxel based therapy. J Clin Oncol (suppl.), 2014.
  12. Fizazi K Prevention of symptomatic skeletal events in patients with genitourinary tumors and bone metastases treated with denosumab or zoledronic acid. Eur Urol Suppl 13,e869, 2014.
  13. Grünwald, Perspektiven in der Onkologie (1):12-14, Deutsches Ärzteblatt 2015.
  14. Hussain M Primary outcomes of the placebo controlled phase 2 study PERSEUS investigating two dose regimens of abitiuzumab in the treatment of chemotherapy naïve patients with asymptomatic or mildly symptomatic mCRPC. J Clin Oncol suppl 5030,2014.
  15. Klotz L Symptomatic skeletal events in patients with advanced cancer. Results from a phase III trial of denosumab for the prevention of SRE. J Clin Oncol 5075, 2014.
  16. Lipton Effect of denosumab versus zoledronic acid in preventing SREs in patients with metastatic bone ldisease: Subgroup analyses by baseline characteristics. J Clin Oncol 9501, 2014.
  17. Mc Lornan DP et al. Applying synthetic lethality fort he selective targeting of cancer. N Engl J Med 371: 1725-1735, 2014.
  18. Miller K: The phase 3 COU-AA-302 study: stratified analysis based on pain,PSA and Gleason score . Eur Urol Suppl:15(3):86,2016.
  19. Minami T et al. A phase II study of peptide vaccines and dexamethason vs dexamethasone alone for chemonaive CRPC-final report. Eur Urol Suppl 14/2; 666 e, 2015.
  20. Monk P et al. Phase II randomized double blind placebo controlled study of Tivantinib in men with asymptomatic or minimally symptomatic mCRPC. ASCO GU: 146,2015.
  21. Moreira RB: Differential side effeccts profile in mCRPC patients treated with abiraterone or enzalutamide: A metaanalysis of randomized trials. JClinOncol 34:73,2016.
  22. Morris MJ et al. Effect of radium 223 dichloride with docetaxel vs Docetaxel on PSA and bALP in patients with CRPC and bone metastases. J Clin Oncol 33 e 5012, 2015.
  23. Mulders PFA et al. Abiraterone acetate improves overall survival in chemotherapy naïve metastatic CRPC. Eur Urol Suppl 14/2; 556 e, 2015.
  24. Nabhan C Sipuleucel-T in mCRPC patients>80 years old: Data from PROCEED. J Clin Oncol (suppl.), 2014.
  25. Sartor O et al. Prior and concurrent use of abiraterone and enzalutamide with radium 223 dichloride in US EAP. Eur Urol Suppl 14/2; 672 e, 2015.
  26. Sartor O:Radium 223 re-treatment: First experience from an international,multicenter,prospective study in patients withCRPC and bone metastases. JClinOncol34:197,2016.
  27. Smith MR Final analysis of COMET 1. ASCO GU:139,2015
  28. Chi KN et al. Phase III Synergy trial. J Clin Oncol 33 e 5009, 2015.
  29. Petrylak D A phase 2 trial of PSMA ADC in taxane treated mCRPC. Eur Urol Suppl 13,e870, 2014.
  30. Petrylak DP et al. Docetaxel and prdnisone with or without lenalidomide in chemotherapy naïve patients with mCRPC. Lancet Oncol 16: 417-425, 2015. 
  31. Sternberg C A phase 3 randomized double blind placebo controlled study of tasquinimod in men with mCRPC, secondary endpoints. JClinOncol34:239,2016
  32. Zechmann CM et al. Eur J Nucl Med Mol Imaging 41:1280, 2014.
  33. Zhou T: Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic resistant prostate cancer: a systematic review. Asian J Androl in press.

Immuncheckpoint-Inhibition beim Blasenkarzinom

Dr. Claudia Schöllmann, S. 32

  1. Hoffman-Censits J.H. et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J Clin Oncol 34, 2016 (suppl 2S; abstr 355)
  2. Balar A. V. et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. J Clin Oncol 34, 2016 (suppl; abstr LBA4500)
  3.  Balar A.V Oral Abstract Session, Genitourinary (Nonprostate) Cancer, presentation LBA4500
  4. Massard C. et al. Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer. J Clin Oncol 34, 2016 (suppl; abstr 4502)
  5. Massard C. ASCO 2016, Oral Abstract Session, Genitourinary (Nonprostate) Cancer, presentation 4502
  6. Apolo A.B. et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. J Clin Oncol 34, 2016 (suppl; abstr 4514)
  7. Sharma P. et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. J Clin Oncol 34, 2016 (suppl; abstr 4501)

Immuntherapie bei Kopf-Hals-Tumoren

Dr. Claudia Schöllmann, S. 33

  1. Ferris R. L. et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. J Clin Oncol 34, 2016 (suppl; abstr 6009) 
  2. Bauml J et al. Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 34, 2016 (suppl; abstr 6011)
  3. Education Session Integrating Immune Checkpoint Inhibitors and Targeted Agents With Surgery and Radiotherapy for Patients With Head and Neck Cancer., ASCO 2016, 6. Juni 2016: 

Supportivtherapie: Nebenwirkungsmanagement bei Tumorpatienten

Dr. Petra Ortner, ab S. 34

  1. Shmueli ES et al. Safety and activity of topical 4% doxycycline foam (FDX104) in epidermal growth factor receptor inhibitor (EGFRI) induced skin toxicity. J Clin Oncol 34, 2016 (suppl; abstr 10130)
  2. Bower JE et al. Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. J Clin Oncol 2014; 32:1840-1850
  3. Bower JE et al. Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. J Clin Oncol 2014; 32:1840-1850
  4. Cleeland CS et al. Minocycline to reduce chemoradiation-related fatigue in patients with non-small cell lung cancer: A phase II randomized trial. J Clin Oncol 34, 2016 (suppl; abstr 10017)
  5. Miyamoto Y et al. A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402). J Clin Oncol 34, 2016 (suppl; abstr 10127)
  6. Peppone LJ et al. Omega-3 (?3) supplementation versus omega-6 (?6) supplementation for fatigue among breast cancer survivors: A URCC NCORP RCT. J Clin Oncol 34, 2016 (suppl; abstr 10128)
  7. Matsuzaki K et al. Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. J Clin Oncol 34, 2016 (suppl; abstr 10019)
  8. Hashimoto H et al. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. J Clin Oncol 34, 2016 (suppl; abstr 10111)
  9. Kurbacher CM et al. Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in women treated for either breast or female genital tract cancer: A German experience using the Paxman system. J Clin Oncol 34, 2016 (suppl; abstr 10118)
  10. Hershman DL et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014;32:1941-1976
  11. Hershman DL et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials. J Clin Oncol 34, 2016 (suppl; abstr 10001)
  12. Greenlee H et al. Body mass index, lifestyle factors, and taxane-induced neuropathy in women with breast cancer: The Pathways Study. J Clin Oncol 34, 2016 (suppl; abstr 10002)
  13. Kleckner I et al. A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients.
  14. Hanai A et al. The effects of frozen gloves and socks on paclitaxel-induced peripheral neuropathy among patients with breast cancer: A self-controlled clinical trial. J Clin Oncol 34, 2016 (suppl; abstr 10022)
  15. Vitale MG et al. Does oral alpha lipoic acid prevent oxaliplatin-induced peripheral neuropathy? A randomized, double-blind, parallel-arm, placebo-controlled trial. J Clin Oncol 34, 2016 (suppl; abstr 10117)
  16. Glimelius B et al. Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 34, 2016 (suppl; abstr 10018)
  17. Zhang L et al. A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients. J Clin Oncol 34, 2016 (suppl; abstr TPS10142) 

21. Kongress der European Hematology Association

Dr. Susanne Heinzl, ab S. 36

  1. Dimopoulos MA, et al. Abstract LB2238
  2. Topp M, et al. Abstract S149
  3. Richter J, et al. Abstract S145
  4. Melazzini F, et al. Abstract S148
  5. Metzeler K, et al. Abstract S146

Fortschritt auch für ältere Brustkrebspatientinnen

Friederike Klein, ab S. 42

  1. Gesundheitsberichterstattung des Bundes gemeinsam getragen von RKI und destatis. Gesundheit in Deutschland 2015, Berlin, November 2015. www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesInDtld/GesInDtld_inhalt.html, letzter Download 8.Juni 2016
  2. de Glas NA et al. Eur J Cancer 2015; 51: 310-6
  3. Bastiaannet E et al. Oncologist 2011; 16: 415–23
  4. Walter LC et al. JAMA 2001; 285: 2750-6
  5. Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie e. V. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Stand April 2016, www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/ zuletzt heruntergeladen 7. Juni 2016
  6. Scher KS, Hurria A. J Clin Oncol. 2012; 30: 2036-8
  7. Harbeck N. Die ältere Brustkrebs-Patientin. Symposium: Solide Tumoren bei älteren Patienten. 32. Deutscher Krebskongress, Berlin, 26. Februar 2016
  8. Kunkler IH et al. Lancet Oncol 2015; 16: 266-73
  9. Muss HB et al. N Engl J Med 2009; 360: 2055-65
  10. Coleman R et al. SABCS 2013, Abstract S4-07
  11. Bignazoli L et al. Lancet Oncol 2012; 13: e148-60

Therapie des Magen- und Pankreaskarzinoms

Update Dr. Maren Knödler und Dr. Marianne Sinn, ab S. 46

 

  1. De Angelis R et al (2014) Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 15(1):23-34. 
  2. Sobin LH et al (2010) TNM-Klassifikation maligner Tumoren, 7. Auflage Willey-VCH, Weinheim
  3. Cancer Genome Atlas Research Network. (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513(7517):202-9.
  4. Cristescu R et al (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 221(5):449-56. 
  5. Moehler M et al (2011) German S3-Guideline “Diagnosis and Treatment of Esophagogastric Cancer”. Z Gastroenterol. 49:461-531.
  6. Cunningham D et al (2011) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20.
  7. Ychou M et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721
  8. Schuhmacher C et al (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 28:5210-8. 
  9. Allum WH et al (2009) Long term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27:5062–5066
  10. Bang YJ et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 379(9813):315-21.
  11. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA.303:1729-37.
  12. Noh SH et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 15:1389-96.
  13. Macdonald JS et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725-30.
  14. Verheij M et al (2016) A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. J Clin Oncol 34, 2016 (suppl; abstr 4000)
  15. Wagner AD et al (2010) Chemotherapy for advanved gastric cencer. Cochrane Database Syst. Rev. 3:CD004064  
  16. Lordick F et al (2014) Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer. 17(2):213-25. 
  17. Al-Batran SE et al (2016) An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol 34, 2016 (suppl; abstr 4001)
  18. Cunningham D et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358(1):36-46
  19. Al-Batran SE et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 26(9):1435-42. 
  20. Van Cutsem et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 24(31):4991-7.
  21. Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376(9742):687-97
  22. Thuss-Patience et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 47(15):2306-14.
  23. Ford HE et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 15(1):78-86.
  24. Kang JH (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 30(13):1513-8.
  25. Fuchs et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 383(9911):31-9.
  26. Wilke H et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15(11):1224-35.
  27. Robert-Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland 2009/2010. In: 9 Ausgabe, Berlin 2013. 
  28. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. August 2014;25(8):1650–6. 
  29. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 11. September 2014;371(11):1039–49. 
  30. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. August 2000;6(8):2969–72. 
  31. Hidalgo M. Pancreatic cancer. N Engl J Med. 29. April 2010;362(17):1605–17. 
  32. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, u. a. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. April 2011;17(4):500–3. 
  33. Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, u. a. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med. März 2016;22(3):278–87. 
  34. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 15. August 2012;18(16):4266–76. 
  35. Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, u. a. [S3-guideline exocrine pancreatic cancer]. Z Gastroenterol. Dezember 2013;51(12):1395–440. 
  36. Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol. 15. März 2016;8(3):248–57. 
  37. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, u. a. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 9. Oktober 2013;310(14):1473–81. 
  38. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, u. a. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 8. September 2010;304(10):1073–81. 
  39. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol [Internet]. [zitiert 1. Juli 2016]; Verfügbar unter: meetinglibrary.asco.org/content/162546-176
  40. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol [Internet]. [zitiert 1. Juli 2016]; Verfügbar unter: meetinglibrary.asco.org/content/116237-132
  41. Sinn M, Liersch T, Gellert K, Messmann H, Bechstein WO, Waldschmidt D, u. a. CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks--A prospective randomized phase III study. ASCO Meeting Abstracts. 20. Mai 2015;33(15_suppl):4007. 
  42. Sinn M, Liersch T, Gellert K, Riess H, Stübs P, Waldschmidt DT, u. a. Conko-006: A Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer. Ann Oncol. 9. Januar 2014;25(suppl 4):mdu438.18. 
  43. Heestand GM, Murphy JD, Lowy AM. Approach to Patients With Pancreatic Cancer Without Detectable Metastases. J Clin Oncol. 1. Juni 2015;33(16):1770–8. 
  44. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, u. a. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13. 
  45. Ko AH. Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities. J Clin Oncol. 1. Juni 2015;33(16):1779–86. 
  46. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, u. a. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 20. Mai 2007;25(15):1960–6. 
  47. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, u. a. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 12. Mai 2011;364(19):1817–25. 
  48. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, u. a. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 31. Oktober 2013;369(18):1691–703. 
  49. Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, u. a. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 3. Mai 2016;315(17):1844–53. 
  50. Sinn M, Dälken L, Striefler JK, Bischoff S, Schweitzer N, Pelzer U, u. a. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?-Results From the CONKO Study Group. Pancreas. April 2016;45(4):601–5. 
  51. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, u. a. Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. J Clin Oncol. 10. August 2014;32(23):2423–9. 
  52. Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, u. a. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 6. Februar 2016;387(10018):545–57. 
  53. Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, u. a. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. JCO. 20. Juni 2015;33(18):2028–34.